Low ERCC1 expression is associated with prolonged survival in patients with bladder cancer receiving platinum-based neoadjuvant chemotherapy
Urologic Oncology: Seminars and Original Investigations, 08/08/2012
Ozcan MF et al. – The authors' results showed that high excision repair cross–complementation group 1 enzyme (ERCC1) expression was independently associated with shorter disease–free and overall survival in patients with bladder cancer who received neoadjuvant platinum–based chemotherapy. ERCC1 may represent a potential predictive marker for platinum–based treatment in bladder cancer.